Media stories about Paratek Pharmaceuticals (NASDAQ:PRTK) have trended somewhat positive on Wednesday, according to Accern Sentiment. The research firm ranks the sentiment of news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Paratek Pharmaceuticals earned a news impact score of 0.19 on Accern’s scale. Accern also assigned news articles about the specialty pharmaceutical company an impact score of 46.1321713125051 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Shares of Paratek Pharmaceuticals (NASDAQ:PRTK) traded down $0.10 during midday trading on Wednesday, hitting $17.75. The stock had a trading volume of 294,100 shares, compared to its average volume of 311,060. Paratek Pharmaceuticals has a 52 week low of $13.95 and a 52 week high of $29.00. The company has a quick ratio of 10.53, a current ratio of 10.53 and a debt-to-equity ratio of 0.49. The stock has a market capitalization of $495.95, a price-to-earnings ratio of -4.76 and a beta of 0.70.
Paratek Pharmaceuticals (NASDAQ:PRTK) last issued its quarterly earnings data on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.77) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.93) by $0.16. Paratek Pharmaceuticals had a negative return on equity of 100.84% and a negative net margin of 1,236.38%. analysts anticipate that Paratek Pharmaceuticals will post -3.32 EPS for the current year.
ILLEGAL ACTIVITY WARNING: This article was posted by Ticker Report and is owned by of Ticker Report. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright law. The correct version of this article can be viewed at https://www.tickerreport.com/banking-finance/3142735/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-paratek-pharmaceuticals-prtk-stock-price.html.
Paratek Pharmaceuticals Company Profile
Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.
Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.